Pancreatic cancer is one of the deadliest forms of cancer, largely because it is often diagnosed too late for effective treatment. Researchers at Wenzhou Medical University have discovered a potential breakthrough: using blood platelets to detect pancreatic cancer early through RNA sequencing. Their study, published in British Journal of Cancer, suggests that specific RNA markers in platelets could serve as reliable, non-invasive diagnostic tools.

Platelets as Cancer Biomarkers

Platelets, typically known for their role in blood clotting, have recently emerged as key players in cancer detection. Cancer cells can influence platelets by transferring RNA molecules into them, altering their gene expression profiles. By analyzing these changes, scientists can potentially identify cancer at its earliest stages.

The Study: Identifying a Two-RNA Signature

The researchers analyzed 673 platelet samples from multiple cohorts using RNA sequencing and RT-qPCR to detect RNA expression differences between pancreatic cancer patients and healthy individuals. Two specific RNA molecules, SCN1B and MAGOHB, consistently showed distinct expression patterns in cancer patients. The researchers then developed a diagnostic signature, PLA2Sig, based on these RNA markers.

Promising Diagnostic Accuracy

The performance of PLA2Sig in detecting pancreatic cancer was impressive. Across different patient groups, its accuracy, measured by the area under the receiver operating characteristic curve (AUC), ranged from 0.783 to 0.900. Notably, it effectively identified patients with early-stage (Stage I & II) pancreatic cancer with an AUC of 0.812. Even more importantly, PLA2Sig outperformed traditional blood-based markers like carcinoembryonic antigen (CEA) and carbohydrate antigen 19-9 (CA19-9), offering a promising alternative for early cancer screening.

Implications for Early Cancer Detection

The ability to detect pancreatic cancer through a simple blood test could significantly improve survival rates by enabling earlier intervention. While further validation is needed before this approach can be widely used in clinical settings, the study highlights the potential of platelet RNA sequencing as a powerful liquid biopsy tool.

This research underscores the growing role of RNA sequencing in cancer diagnostics and opens the door for future studies on platelet-based biomarkers for other diseases.